ADAG Stock Analysis: Buy, Sell, or Hold?
ADAG - Adagene Inc. American Depositary Shares
$4.61
0.69 (17.60%)
▲
5d:
+13.27%
30d:
+55.22%
90d:
+153.85%
WAIT
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 01, 2026
0d
Get Alerted When ADAG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ADAG is 15.3% above fair value ($4.00). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ADAG is 15.3% above fair value ($4.00). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ADAG is currently trading at $4.61, which is considered extended relative to its 30-day fair value range of $3.05 to $4.00.
Technical Outlook: Technically, ADAG is in a strong uptrend. The price is approaching resistance at $4.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 17.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.51 (+106.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADAG is in a strong uptrend. The price is approaching resistance at $4.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 17.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.51 (+106.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$3.05 -
$4.00
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+15.3% above fair value)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+17.6%)
- BULLISH: Trading 106.4% below Wall St target ($9.51)
- WARNING: Recommendation downgraded due to 15.3% overvaluation
Fair Price Analysis
30-Day Fair Range
$3.05 -
$4.00
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$3.44
Resistance Level
$4.35
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.40
Wall Street Target
$9.51
(+106.4%)
Revenue Growth (YoY)
-87.3%
Share & Embed Analysis
Last updated: April 02, 2026 9:12 AM ET
Data refreshes hourly during market hours. Next update: 10:12 AM
Data refreshes hourly during market hours. Next update: 10:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADAG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 57 HOLD |
